WARSAW, Ind., Sep 29, 2003 /PRNewswire-FirstCall via COMTEX/ --
Zimmer Holdings, Inc. (NYSE: ZMH) announced that it plans to locate the head office for its European and Australasia business in Winterthur, Switzerland. Zimmer expects to close on October 2, 2003 its exchange offer for Centerpulse AG, a leading European orthopaedics company with significant manufacturing, R&D and Medical Education facilities at its Winterthur location. In a separate announcement, Mr. Richard Fritschi, formerly President of Centerpulse Europe/Asia/Latin America, was named President of Zimmer Europe and Australasia.
"Winterthur's history as a base of orthopaedic innovation extends back to the early 1960s when materials research at Sulzer, which was formed in 1834, led to development of artificial joint replacement products. We believe that this historical and present relationship to the city of Winterthur and its people should be preserved and grown," said Ray Elliott, Zimmer Chairman, President and CEO. "We gave careful consideration to both Milan and Zurich but, in the end, we believe the choice of Winterthur is in the best interest of the entire company. We look forward to working with the Winterthur employees, citizens and city officials as Zimmer becomes part of the local community."
Zimmer plans to announce other details of its combined structure at the time the transaction closes.
Safe Harbor Statement
This press release contains forward-looking statements based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, price and product competition, rapid technological development, demographic changes, dependence on new product development, the mix of our products and services, supply and prices of raw materials and products, customer demand for our products and services, our ability to successfully integrate acquired companies, control of costs and expenses, our ability to form and implement alliances, international growth, U.S. and foreign government regulation, product liability and intellectual property litigation losses, reimbursement levels from third-party payors, general industry and market conditions and growth rates and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see the disclosure materials filed by Zimmer with the U.S. Securities and Exchange Commission. Zimmer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.
About Zimmer Holdings, Inc.
Zimmer, based in Warsaw, Indiana, is a worldwide leader in the design, development, manufacture and marketing of reconstructive orthopaedic implants and trauma products. Orthopaedic reconstruction implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Trauma products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body's natural healing process. Zimmer manufactures and markets other products related to orthopaedic surgery. The combination of Zimmer and Centerpulse will create the world's #1 pure-play orthopaedics company with more than $2.2 billion in combined 2002 sales and 7000 employees.
SOURCE Zimmer Holdings, Inc.
Media - Brad Bishop, Public Affairs, +1-574-372-4291, or email, email@example.com, or Investors - Sam Leno, Chief Financial Officer, +1-574-372-4790, or email, firstname.lastname@example.org, both of Zimmer Holdings, Inc.; or Switzerland - Aloys Hirzel, +41 43 344 42 49, or email, email@example.com, or Andreas Thommen, +41 43 344 42 49, or email, firstname.lastname@example.org, both of Hirzel. Neef. Schmid. Konsulenten; or U.K. - Hugh Morrison, +44 207 153 1534, or email, email@example.com, or Nick Miles, +44 207 153 1535, or email, firstname.lastname@example.org, both of M Communications
Copyright (C) 2003 PR Newswire. All rights reserved.
News Provided by COMTEX